| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MED20 |
| Uniprot No | Q9H944 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-212aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMGVTCVSQMPVAEGKSVQQTVELLTRK LEMLGAEKQGTFCVDCETYHTAASTLGSQGQTGKLMYVMHNSEYPLSCFA LFENGPCLIADTNFDVLMVKLKGFFQSAKASKIETRGTRYQYCDFLVKVG TVTMGPSARGISVEVEYGPCVVASDCWSLLLEFLQSFLGSHTPGAPAVFG NRHDAVYGPADTMVQYMELFNKIRKQQQVPVAGIR |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及MED20重组蛋白的相关文献信息整理：
1. **文献名称**：Structural and functional analysis of the human Med20 subunit in the Mediator complex
**作者**：Tóth-Petróczy A, et al.
**摘要**：研究解析了人源MED20亚基在中介体复合物中的结构特征，通过重组表达纯化MED20并分析其与RNA聚合酶II的相互作用机制，揭示了其在转录起始中的调控作用。
2. **文献名称**：Recombinant expression and biochemical characterization of Mediator subunit Med20 from Saccharomyces cerevisiae
**作者**：Bourbon HM, et al.
**摘要**：报道了酿酒酵母MED20的重组表达与纯化方法，发现该蛋白通过特定结构域参与中介体复合物的组装，并影响基因转录激活过程。
3. **文献名称**：The Mediator complex subunit MED20 regulates longevity in Caenorhabditis elegans
**作者**：Zhang H, et al.
**摘要**：利用重组MED20蛋白进行功能实验，证明其通过调控胰岛素信号通路影响线虫寿命，揭示了该亚基在跨物种中的保守性及代谢相关转录调控功能。
**备注**：MED20作为中介体复合物的非核心亚基，直接研究其重组蛋白的文献较少，更多信息可结合中介体复合物整体结构或转录调控相关研究进行扩展检索。
**Background of MED20 Recombinant Protein**
The MED20 protein is a subunit of the Mediator complex, a multi-protein assembly essential for regulating transcription by RNA polymerase II (Pol II) in eukaryotes. The Mediator complex acts as a molecular bridge, integrating signals from transcription factors and co-regulators to modulate Pol II activity at gene promoters. MED20. part of the Mediator’s head module, plays a structural and functional role in stabilizing the interaction between Mediator and Pol II, facilitating the assembly of the pre-initiation complex.
MED20 is evolutionarily conserved, underscoring its critical role in transcriptional regulation. Studies suggest its involvement in maintaining Mediator integrity, as disruptions to MED20 impair complex stability and compromise transcription initiation. Recombinant MED20 protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), enables detailed biochemical and structural studies. These include investigating its interactions with other Mediator subunits (e.g., MED8. MED18) or Pol II, mapping binding interfaces, and analyzing mutations linked to transcriptional dysregulation.
Research on MED20 also extends to disease contexts. Dysregulation of Mediator subunits, including MED20. has been implicated in cancers and developmental disorders. For example, aberrant MED20 expression correlates with tumor progression in certain cancers, potentially through altered transcriptional programs driving cell proliferation. Recombinant MED20 aids in elucidating such mechanisms, screening for therapeutic compounds, or engineering mutants to dissect functional domains.
In summary, MED20 recombinant protein serves as a vital tool for decoding Mediator-dependent transcription mechanisms, understanding disease pathways, and developing targeted interventions. Its study bridges molecular biology, structural biology, and translational research.
×
